ClinicalTrials.gg
CompletedNCT04533529Updated May 12, 2026Results posted

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

A Phase 3 interventional study of Seltorexant and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 122 sites in 11 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
588
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.

Enrollment
4th of 12
588 · median 176
Started
2020
with 3 others
Phase 3
5 of 12
2 open now
Registered
8th of 12
by date
Lead sponsor
11 of 12
Janssen Research & Development, LLC

Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one is the 4th largest by enrollment, is one of 4 that started in 2020, is one of 5 in phase 3, and was the 8th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About seltorexant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing seltorexant in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with an selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in double-blind treatment phase and to assess the long-term safety and tolerability of seltorexant as adjunctive therapy to an antidepressant in participants with major depressive disorder (MDD) in open-label treatment phase.

Read the detailed description

Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for adjunctive treatment of major depressive disorder with insomnia symptoms (MDDIS). The hypothesis for this study is that adjunctive treatment with seltorexant is superior to placebo in treating depressive symptoms, as measured by change in Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline to Day 43 in adult and elderly participants with MDDIS who have had an inadequate response to treatment with a SSRI/SNRI. The study will be conducted in 4 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (43 days), open label (OL) treatment phase (1-year), and a post treatment follow-up phase (7 to 14 days after end of treatment). The total study duration for each participant will be up to 64 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet -5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Structured Clinical Interview for DSM-5 Axis I Disorders-Clinical Trials Version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (\<=) 24 months prior to randomization
  • Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (\<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms beyond insomnia present, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
  • Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
  • (BMI) between 18 and 40 kilograms per meter square (kg/m\^2), inclusive (BMI = weight/height\^2)
  • Participant must be medically stable on the basis of the following performed at screening: physical examination (including a brief neurological examination), vital signs (including blood pressure), and 12-lead (ECG) performed at screening and baseline

Exclusion criteria

Exclusion Criteria:

  • Has a recent (last 3 months) history of, or current signs and symptoms of, a) severe renal insufficiency ( [CrCl] \<30 milliliter per minute [mL/min]); b) or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders; c) uncontrolled Type 1 or Type 2 diabetes mellitus
  • Has a current or recent history of homicidal ideation or serious suicidal ideation within the past 3 months, corresponding to a positive response on item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) for ideation on the Columbia Suicide Severity Rating Scale (C-SSRS), or a history of suicidal behavior within the past 6 months, as validated by the C-SSRS at screening or Day 1. Participants with prior suicidal behavior in the past year, or prior serious suicidal ideation/plan within the past 6 months, should be carefully screened. For current suicidal ideation, only participants with non serious items (1-3 of the suicidal ideation section of the C-SSRS) may be included at the discretion of the investigator
  • Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (\<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
  • Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, or somatoform disorders
  • Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
  • Has a history of moderate to severe substance use disorder including alcohol use disorder according to criteria within 6 months before screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
588 participants (actual)

Study arms

  • Experimental
    Seltorexant

    Participants will receive seltorexant tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase. Eligible participants who will enter the open label (OL) treatment phase will receive seltorexant tablet daily from OL baseline until the end of phase/ early withdrawal (EW) visit (Up to 1 Year).

    Drug: Seltorexant

  • Placebo comparator
    Placebo

    Participants will receive matching placebo tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase.

    Drug: Placebo

Interventions

  • Seltorexant tablet will be administered orally once daily.

    Also known as: JNJ-42847922

  • DrugPlacebo

    Matching placebo tablet will be administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1

    The MADRS is a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant intervention. Scale has 10 items(apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) each of which was scored from 0 (not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is sum of scores from individual question items, which ranged from 0 to 60. Higher scores indicates more severe condition. Negative changes in MADRS total score indicates improvement.

    Time frame: Baseline (Day 1), Day 43

  2. Open Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study drug. Treatment emergent AEs was defined as any AE occurred at or after the initial administration of study intervention through the day of last dose plus 2 days.

    Time frame: From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)

  3. OL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)

    AE was defined as any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study drug. Treatment emergent AEs was defined as any AE occurred at or after the initial administration of study intervention through the day of last dose plus 2 days. The AEs considered to be of special interest: cataplexy, sleep paralysis, complex, sleep-related behaviors/parasomnias such as confusional arousals, somnambulism, sleep terrors, bruxism, sleep sex, sleep-related eating disorder, and catathrenia, fall, motor vehicle accident.

    Time frame: From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)

  4. OL Treatment Phase: Change From Baseline in Vital Signs: Blood Pressure

    Change from baseline in vital signs: systolic/diastolic blood pressure were reported. Blood pressure measurements were assessed with the participant in a sitting position using a completely automated device.

    Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52

  5. OL Treatment Phase: Change From Baseline: Body Mass Index (BMI)

    Change from baseline in BMI were reported.

    Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52

  6. OL Treatment Phase: Change From Baseline in Vital Signs: Temperature

    Change from baseline in vital signs: temperature were reported.

    Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52

  7. OL Treatment Phase: Change From Baseline in Vital Signs: Pulse Rate

    Change from baseline in vital signs: pulse rate were reported. Pulse rate measurements were assessed with the participant in a sitting position using a completely automated device.

    Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52

  8. OL Treatment Phase: Change From Baseline in Weight

    Change from baseline in weight was reported.

    Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52

  9. OL Treatment Phase: Change From Baseline in Waist Circumference

    Change from baseline in waist circumference were reported.

    Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52

  10. OL Treatment Phase: Number of Participants With Shift From Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent), Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranged from 0 to 10, higher total scores indicate more suicidal ideation and/or suicidal behavior. Categories with at least 1 non-zero data values are reported.

    Time frame: From DB Baseline (Day 1) up to Week 52

  11. OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Start of OL Follow Up

    The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization) evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.

    Time frame: Start of OL Follow Up (Week 52)

  12. OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 1

    The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization) evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.

    Time frame: Follow up Visit 1: 1 day after end of OL phase (Week 52.14)

  13. OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 2

    The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization)evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.

    Time frame: Follow Up Visit 2: 2 weeks after end of OL phase (Week 54)

  14. OL Treatment Phase: Number of Participants With Electrocardiogram (ECG) Abnormalities

    Number of participants with ECG abnormalities during OL treatment phase was reported. ECG abnormalities were assessed as per investigator's discretion.

    Time frame: Week 52

  15. OL Treatment Phase: Number of Participants With Clinically Significant Laboratory Abnormalities

    Laboratory parameters: hematology (platelet count, red blood cell \[RBC\] count, hemoglobin, hematocrit, neutrophils (Segmented/Leukocytes), lymphocytes, monocytes, eosinophils/leukocytes \[Eos/Leu\], basophils, Reticulocytes/ Erythrocytes \[Reti/Ery\]); chemistry (sodium, potassium, chloride, bicarbonate, creatinine, Creatine Kinase, glucose, aspartate transaminase \[AST\], alanine transaminase \[ALT\], gamma-glutamyl transferase \[GGT\], alkaline phosphatase, total bilirubin, phosphate, albumin, total protein, total cholesterol, high-density lipoprotein, low-density lipoprotein, Triglycerides); urine (specific gravity, pH, glucose, blood, bilirubin, urobilinogen, RBC). Clinically significant abnormalities (low/high) were determined at the investigator's discretion. Only those categories in which at least one participant had data were reported in this outcome measure.

    Time frame: From DB Baseline (Day 1) to Week 52

  16. OL Treatment Phase: Number of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Score

    ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction. Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items.

    Time frame: Week 52

Secondary outcomes

  1. DB Treatment Phase: Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score- Estimand 1

    The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. The MADRS-WOSI evaluated apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.

    Time frame: Baseline (Day 1), Day 43

  2. DB Treatment Phase: Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (8a) T-Score: Estimand 1

    PROMIS-SD Short Form 8a is a static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has five response options ranging in value from 1 to 5. Direction of responses was not same, sometimes "not at all" represents more sleep disturbance; sometimes "not at all" indicates less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores indicate less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean: 50; standard deviation: 10. Negative changes in scores indicates improvement. Higher values represent more severe sleep disturbance.

    Time frame: Baseline (Day 1), Day 43

  3. DB Treatment Phase: Change From Baseline to Day 43 in the MADRS-6 Total Score: Estimand 1

    The 6-item MADRS was a clinician-administered scale designed to measure the core symptoms of depression severity and detected changes due to antidepressant intervention. It is a subset of MADRS (10-item). The MADRS-6 subscale score was the sum of scores for the following MADRS items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item is scored from 0 (item not present or normal) to 6 (most severe or continuous presence of symptoms); the overall score ranges from 0 to 36, higher scores represented a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline (Day 1), Day 43

  4. DB Treatment Phase: Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS at Day 43

    Percentage of participants with response on depressive symptoms scale based on MADRS total score at Day 43 were reported. Responders were defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS is a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant intervention. Scale has 10 items(apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) each of which was scored from 0 (not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is sum of scores from individual question items, which ranged from 0 to 60. Higher scores indicates more severe condition. Negative changes in MADRS total score indicates improvement.

    Time frame: At Day 43

  5. DB Treatment Phase: Change From Baseline to Day 43 in Patient Health Questionnaire 9-item (PHQ-9) Total Score

    The PHQ-9 was a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) MDD criteria. Each item was rated on a 4 points scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicated improvement.

    Time frame: Baseline (Day 1), Day 43

  6. OL Treatment Phase: Change From Baseline Over Time in MADRS Total Score

    MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms). MADRS total score was sum of scores from individual question items, which ranged from 0-60. Higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

    Time frame: OL Baseline (Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  7. OL Treatment Phase: Change From Baseline Over Time in the Clinical Global Impression-Severity (CGI-S) Score

    The CGI-S (depression) provided an overall clinician-determined summary measure of severity of the participant's illness that considers all available information, included knowledge of participant's history, psychosocial circumstances, symptoms, behavior, impact of symptoms on participant's ability to function. CGI-S evaluated severity of psychopathology on a scale of 1 to 7. The CGI-S was 7-point global assessment scale that measures clinician's impression of severity of illness, rating: 1=normal (not at all ill), 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants, with higher scores indicate worsening. Negative changes in CGI-S score indicate improvement.

    Time frame: OL Baseline (Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  8. OL Treatment Phase: Change From Baseline Over Time in the MADRS-WOSI Total Score

    The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. The MADRS-WOSI evaluated apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.

    Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  9. OL Treatment Phase: Change From Baseline Over Time in Sleep Disturbance Using the PROMIS-SD Short Form 8a T-Score

    PROMIS-SD Short Form 8a is a static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has five response options ranging in value from one to five. Direction of responses was not same, sometimes "not at all" represents more sleep disturbance; sometimes "not at all" indicates less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores indicate less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean:50; standard deviation:10. Negative changes in scores indicates improvement. Higher values represent more severe sleep disturbance.

    Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

07

Results

Posted May 12, 2026

Participant flow

DB Treatment Phase (Day 1 to Day 43)
Participant flow — DB Treatment Phase (Day 1 to Day 43)
MilestoneDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mgDB Follow-up Phase: PlaceboDB Follow-up Phase: Seltorexant 20 mgOL Follow-up Phase: Placebo to Seltorexant 20 mgOL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg
Started304284000000
Treated303283000000
Completed277263000000
Not completed2721000000
Withdrew: Adverse event55000000
Withdrew: Lack of efficacy10000000
Withdrew: Lost to follow-up21000000
Withdrew: Physician decision02000000
Withdrew: Pregnancy01000000
Withdrew: Protocol deviation12000000
Withdrew: Withdrawal by subject116000000
Withdrew: Initiated prohibited medication10000000
Withdrew: Non-compliance with primary antidepressant20000000
Withdrew: Non-compliance with study drug33000000
Withdrew: Randomized but not treated11000000
OL Treatment Phase (Day 43 to Week 52)
Participant flow — OL Treatment Phase (Day 43 to Week 52)
MilestoneDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mgDB Follow-up Phase: PlaceboDB Follow-up Phase: Seltorexant 20 mgOL Follow-up Phase: Placebo to Seltorexant 20 mgOL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg
Started002692530000
Completed001761840000
Not completed0093690000
Withdrew: Adverse event0022110000
Withdrew: Death00010000
Withdrew: Lack of efficacy0012100000
Withdrew: Lost to follow-up00850000
Withdrew: Physician decision00010000
Withdrew: Protocol deviation00300000
Withdrew: Withdrawal by subject0036280000
Withdrew: Other00110000
Withdrew: Non-compliance with study drug00650000
Withdrew: Initiated prohibited medication00330000
Withdrew: Non-compliance with primary antidepressant00120000
Withdrew: Site terminated by sponsor00120000
DB Follow-up Phase (Day 43 to Day 57)
Participant flow — DB Follow-up Phase (Day 43 to Day 57)
MilestoneDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mgDB Follow-up Phase: PlaceboDB Follow-up Phase: Seltorexant 20 mgOL Follow-up Phase: Placebo to Seltorexant 20 mgOL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg
Started0000222200
Completed0000181500
Not completed00004700
Withdrew: Adverse event00000200
Withdrew: Lost to follow-up00001000
Withdrew: Other00001100
Withdrew: Withdrawal by subject00002400
OL Follow-up Phase (Week 52 to Week 54)
Participant flow — OL Follow-up Phase (Week 52 to Week 54)
MilestoneDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mgDB Follow-up Phase: PlaceboDB Follow-up Phase: Seltorexant 20 mgOL Follow-up Phase: Placebo to Seltorexant 20 mgOL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg
Started000000228225
Completed000000214211
Not completed0000001414
Withdrew: Withdrawal by subject00000088
Withdrew: Adverse event00000031
Withdrew: Lost to follow-up00000023
Withdrew: Site terminated by sponsor00000001
Withdrew: Other00000011

Outcome measures

PrimaryDouble Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1

The MADRS is a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant intervention. Scale has 10 items(apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) each of which was scored from 0 (not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is sum of scores from individual question items, which ranged from 0 to 60. Higher scores indicates more severe condition. Negative changes in MADRS total score indicates improvement.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · Units on a scale
Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1
Units on a scaleDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mg
Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1-10.5 ± 10.26-12.9 ± 9.63
Statistical analysis
  • Double Blind (DB) Treatment Phase: Placebo vs DB Treatment Phase: Seltorexant 20 mg · mixed model repeated measures (MMRM) · p = =0.007 · Least square (ls) mean difference: -2.6 · 95% CI -4.53 to -0.74
PrimaryOpen Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study drug. Treatment emergent AEs was defined as any AE occurred at or after the initial administration of study intervention through the day of last dose plus 2 days.

Time frame:
From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
Reported as:
Count of participants · Participants
Open Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
Open Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)167163
PrimaryOL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)

AE was defined as any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study drug. Treatment emergent AEs was defined as any AE occurred at or after the initial administration of study intervention through the day of last dose plus 2 days. The AEs considered to be of special interest: cataplexy, sleep paralysis, complex, sleep-related behaviors/parasomnias such as confusional arousals, somnambulism, sleep terrors, bruxism, sleep sex, sleep-related eating disorder, and catathrenia, fall, motor vehicle accident.

Time frame:
From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
Reported as:
Count of participants · Participants
OL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)
ParticipantsOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)108
PrimaryOL Treatment Phase: Change From Baseline in Vital Signs: Blood Pressure

Change from baseline in vital signs: systolic/diastolic blood pressure were reported. Blood pressure measurements were assessed with the participant in a sitting position using a completely automated device.

Time frame:
OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
Reported as:
Mean · Millimeters of mercury (mmHg)
OL Treatment Phase: Change From Baseline in Vital Signs: Blood Pressure
Millimeters of mercury (mmHg)Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
Diastolic Blood Pressure0.1 ± 8.220.9 ± 8.38
Systolic Blood Pressure0.5 ± 10.38-0.5 ± 11.29
PrimaryOL Treatment Phase: Change From Baseline: Body Mass Index (BMI)

Change from baseline in BMI were reported.

Time frame:
OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
Reported as:
Mean · Kilogram per square meter(kg/m^2)
OL Treatment Phase: Change From Baseline: Body Mass Index (BMI)
Kilogram per square meter(kg/m^2)Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Treatment Phase: Change From Baseline: Body Mass Index (BMI)0.44 ± 1.5890.67 ± 1.673
PrimaryOL Treatment Phase: Change From Baseline in Vital Signs: Temperature

Change from baseline in vital signs: temperature were reported.

Time frame:
OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
Reported as:
Mean · Degree Celsius (C)
OL Treatment Phase: Change From Baseline in Vital Signs: Temperature
Degree Celsius (C)Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Treatment Phase: Change From Baseline in Vital Signs: Temperature-0.03 ± 0.3130.01 ± 0.300
PrimaryOL Treatment Phase: Change From Baseline in Vital Signs: Pulse Rate

Change from baseline in vital signs: pulse rate were reported. Pulse rate measurements were assessed with the participant in a sitting position using a completely automated device.

Time frame:
OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
Reported as:
Mean · Beats/min
OL Treatment Phase: Change From Baseline in Vital Signs: Pulse Rate
Beats/minOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Treatment Phase: Change From Baseline in Vital Signs: Pulse Rate0.1 ± 8.280.5 ± 9.31
PrimaryOL Treatment Phase: Change From Baseline in Weight

Change from baseline in weight was reported.

Time frame:
OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
Reported as:
Mean · Kilogram (Kg)
OL Treatment Phase: Change From Baseline in Weight
Kilogram (Kg)Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Treatment Phase: Change From Baseline in Weight1.26 ± 4.3031.80 ± 4.567
PrimaryOL Treatment Phase: Change From Baseline in Waist Circumference

Change from baseline in waist circumference were reported.

Time frame:
OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
Reported as:
Mean · Centimeter (Cm)
OL Treatment Phase: Change From Baseline in Waist Circumference
Centimeter (Cm)Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Treatment Phase: Change From Baseline in Waist Circumference0.5 ± 5.950.7 ± 5.95
PrimaryOL Treatment Phase: Number of Participants With Shift From Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent), Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranged from 0 to 10, higher total scores indicate more suicidal ideation and/or suicidal behavior. Categories with at least 1 non-zero data values are reported.

Time frame:
From DB Baseline (Day 1) up to Week 52
Reported as:
Count of participants · Participants
OL Treatment Phase: Number of Participants With Shift From Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
Baseline: No SI/SB to Postbaseline No SI/SB204190
Baseline: No SI/SB to Postbaseline Suicidal Ideation1815
Baseline: No SI/SB to Postbaseline Suicidal Behavior40
Baseline: Suicidal ideation to Postbaseline No SI/SB1816
Baseline: Suicidal ideation to Postbaseline Suicidal Ideation2430
Baseline: Suicidal ideation to Postbaseline Suicidal Behavior12
PrimaryOL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Start of OL Follow Up

The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization) evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.

Time frame:
Start of OL Follow Up (Week 52)
Reported as:
Mean · Units on a scale
OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Start of OL Follow Up
Units on a scaleOL Follow-up Phase: Placebo to Seltorexant 20 mgOL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Start of OL Follow Up7.8 ± 8.487.4 ± 8.27
PrimaryOL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 1

The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization) evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.

Time frame:
Follow up Visit 1: 1 day after end of OL phase (Week 52.14)
Reported as:
Mean · Units on a scale
OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 1
Units on a scaleOL Follow-up Phase: Placebo to Seltorexant 20 mgOL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 16.2 ± 7.625.5 ± 7.04
PrimaryOL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 2

The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization)evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.

Time frame:
Follow Up Visit 2: 2 weeks after end of OL phase (Week 54)
Reported as:
Mean · Units on a scale
OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 2
Units on a scaleOL Follow-up Phase: Placebo to Seltorexant 20 mgOL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 26.3 ± 6.767.1 ± 8.04
PrimaryOL Treatment Phase: Number of Participants With Electrocardiogram (ECG) Abnormalities

Number of participants with ECG abnormalities during OL treatment phase was reported. ECG abnormalities were assessed as per investigator's discretion.

Time frame:
Week 52
Reported as:
Count of participants · Participants
OL Treatment Phase: Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Treatment Phase: Number of Participants With Electrocardiogram (ECG) Abnormalities2726
PrimaryOL Treatment Phase: Number of Participants With Clinically Significant Laboratory Abnormalities

Laboratory parameters: hematology (platelet count, red blood cell \[RBC\] count, hemoglobin, hematocrit, neutrophils (Segmented/Leukocytes), lymphocytes, monocytes, eosinophils/leukocytes \[Eos/Leu\], basophils, Reticulocytes/ Erythrocytes \[Reti/Ery\]); chemistry (sodium, potassium, chloride, bicarbonate, creatinine, Creatine Kinase, glucose, aspartate transaminase \[AST\], alanine transaminase \[ALT\], gamma-glutamyl transferase \[GGT\], alkaline phosphatase, total bilirubin, phosphate, albumin, total protein, total cholesterol, high-density lipoprotein, low-density lipoprotein, Triglycerides); urine (specific gravity, pH, glucose, blood, bilirubin, urobilinogen, RBC). Clinically significant abnormalities (low/high) were determined at the investigator's discretion. Only those categories in which at least one participant had data were reported in this outcome measure.

Time frame:
From DB Baseline (Day 1) to Week 52
Reported as:
Count of participants · Participants
OL Treatment Phase: Number of Participants With Clinically Significant Laboratory Abnormalities
ParticipantsOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
ALT High12
AST High01
Bicarbonate Low10
Chloride Low10
Cholesterol High711
Creatine Kinase High46
GGT High10
Glucose High10
HDL Cholesterol low1924
Hemoglobin A1C/ Hemoglobin High23
LDL Cholesterol Low4441
LDL Cholesterol High5436
Phosphate low26
Potassium Low11
Potassium High21
Triglycerides High10
Eos/Leu High23
Erythrocytes High14
Hematocrit High35
Leukocytes Low10
Leukocytes High31
Lymphocytes/Leukocytes High20
Lymphocytes/Leukocytes Low15
Neutrophils low41
Neutrophils High01
Platelets Low01
Platelets High02
Reti/Ery Low33
Reti/Ery High7363
Specific Gravity High2522
Urine pH High2432
PrimaryOL Treatment Phase: Number of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Score

ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction. Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items.

Time frame:
Week 52
Reported as:
Count of participants · Participants
OL Treatment Phase: Number of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Score
ParticipantsOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
OL Treatment Phase: Number of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Score124111
SecondaryDB Treatment Phase: Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score- Estimand 1

The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. The MADRS-WOSI evaluated apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · Units on a scale
DB Treatment Phase: Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score- Estimand 1
Units on a scaleDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mg
DB Treatment Phase: Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score- Estimand 1-9.5 ± 9.38-11.4 ± 8.77
Statistical analysis
  • Double Blind (DB) Treatment Phase: Placebo vs DB Treatment Phase: Seltorexant 20 mg · MMRM · p = =0.023 · Ls mean difference: -2 · 95% CI -3.75 to -0.28
SecondaryDB Treatment Phase: Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (8a) T-Score: Estimand 1

PROMIS-SD Short Form 8a is a static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has five response options ranging in value from 1 to 5. Direction of responses was not same, sometimes "not at all" represents more sleep disturbance; sometimes "not at all" indicates less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores indicate less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean: 50; standard deviation: 10. Negative changes in scores indicates improvement. Higher values represent more severe sleep disturbance.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · T-score
DB Treatment Phase: Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (8a) T-Score: Estimand 1
T-scoreDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mg
DB Treatment Phase: Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (8a) T-Score: Estimand 1-7.2 ± 10.60-10.9 ± 9.14
Statistical analysis
  • Double Blind (DB) Treatment Phase: Placebo vs DB Treatment Phase: Seltorexant 20 mg · MMRM · p = <0.001 · Ls mean difference: -3.7 · 95% CI -5.48 to -2.00
SecondaryDB Treatment Phase: Change From Baseline to Day 43 in the MADRS-6 Total Score: Estimand 1

The 6-item MADRS was a clinician-administered scale designed to measure the core symptoms of depression severity and detected changes due to antidepressant intervention. It is a subset of MADRS (10-item). The MADRS-6 subscale score was the sum of scores for the following MADRS items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item is scored from 0 (item not present or normal) to 6 (most severe or continuous presence of symptoms); the overall score ranges from 0 to 36, higher scores represented a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · Units on a scale
DB Treatment Phase: Change From Baseline to Day 43 in the MADRS-6 Total Score: Estimand 1
Units on a scaleDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mg
DB Treatment Phase: Change From Baseline to Day 43 in the MADRS-6 Total Score: Estimand 1-7.1 ± 7.06-8.4 ± 6.79
SecondaryDB Treatment Phase: Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS at Day 43

Percentage of participants with response on depressive symptoms scale based on MADRS total score at Day 43 were reported. Responders were defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS is a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant intervention. Scale has 10 items(apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) each of which was scored from 0 (not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is sum of scores from individual question items, which ranged from 0 to 60. Higher scores indicates more severe condition. Negative changes in MADRS total score indicates improvement.

Time frame:
At Day 43
Reported as:
Number · Percentage of Participants
DB Treatment Phase: Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS at Day 43
Percentage of ParticipantsDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mg
DB Treatment Phase: Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS at Day 4322.935.4
SecondaryDB Treatment Phase: Change From Baseline to Day 43 in Patient Health Questionnaire 9-item (PHQ-9) Total Score

The PHQ-9 was a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) MDD criteria. Each item was rated on a 4 points scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicated improvement.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · Units on a scale
DB Treatment Phase: Change From Baseline to Day 43 in Patient Health Questionnaire 9-item (PHQ-9) Total Score
Units on a scaleDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mg
DB Treatment Phase: Change From Baseline to Day 43 in Patient Health Questionnaire 9-item (PHQ-9) Total Score-5.6 ± 6.62-7.6 ± 6.03
SecondaryOL Treatment Phase: Change From Baseline Over Time in MADRS Total Score

MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms). MADRS total score was sum of scores from individual question items, which ranged from 0-60. Higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

Time frame:
OL Baseline (Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Score on a scale
OL Treatment Phase: Change From Baseline Over Time in MADRS Total Score
Score on a scaleOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
Week 4-6.2 ± 8.48-3.8 ± 7.91
Week 8-7.7 ± 10.03-4.7 ± 8.78
Week 12-8.4 ± 10.04-5.3 ± 9.51
Week 16-9.5 ± 10.28-6.1 ± 10.29
Week 20-9.8 ± 10.81-7.4 ± 10.14
Week 24-9.3 ± 11.67-6.9 ± 10.07
Week 28-10.4 ± 11.31-7.3 ± 10.57
Week 32-11.2 ± 11.87-7.9 ± 10.37
Week 36-10.4 ± 12.47-8.3 ± 10.11
Week 40-11.2 ± 11.96-9.2 ± 10.90
Week 44-12.2 ± 11.62-9.9 ± 10.15
Week 48-12.3 ± 11.51-10.2 ± 9.66
Week 52-12.3 ± 11.37-10.5 ± 9.42
SecondaryOL Treatment Phase: Change From Baseline Over Time in the Clinical Global Impression-Severity (CGI-S) Score

The CGI-S (depression) provided an overall clinician-determined summary measure of severity of the participant's illness that considers all available information, included knowledge of participant's history, psychosocial circumstances, symptoms, behavior, impact of symptoms on participant's ability to function. CGI-S evaluated severity of psychopathology on a scale of 1 to 7. The CGI-S was 7-point global assessment scale that measures clinician's impression of severity of illness, rating: 1=normal (not at all ill), 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants, with higher scores indicate worsening. Negative changes in CGI-S score indicate improvement.

Time frame:
OL Baseline (Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Score on a scale
OL Treatment Phase: Change From Baseline Over Time in the Clinical Global Impression-Severity (CGI-S) Score
Score on a scaleOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
Week 4-0.7 ± 1.05-0.4 ± 0.91
Week 8-1.0 ± 1.15-0.6 ± 1.05
Week 12-1.0 ± 1.22-0.7 ± 1.18
Week 16-1.2 ± 1.32-0.8 ± 1.33
Week 20-1.2 ± 1.36-0.9 ± 1.32
Week 24-1.2 ± 1.46-0.9 ± 1.32
Week 28-1.3 ± 1.45-1.0 ± 1.34
Week 32-1.5 ± 1.37-1.1 ± 1.33
Week 36-1.4 ± 1.50-1.1 ± 1.43
Week 40-1.5 ± 1.46-1.2 ± 1.44
Week 44-1.6 ± 1.49-1.4 ± 1.35
Week 48-1.7 ± 1.47-1.4 ± 1.30
Week 52-1.7 ± 1.44-1.4 ± 1.30
SecondaryOL Treatment Phase: Change From Baseline Over Time in the MADRS-WOSI Total Score

The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. The MADRS-WOSI evaluated apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.

Time frame:
OL Baseline (OL Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Score on a scale
OL Treatment Phase: Change From Baseline Over Time in the MADRS-WOSI Total Score
Score on a scaleOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
Week 4-5.0 ± 7.74-3.3 ± 7.12
Week 8-6.4 ± 9.16-4.2 ± 7.76
Week 12-7.0 ± 9.15-4.7 ± 8.55
Week 16-8.0 ± 9.34-5.3 ± 9.30
Week 20-8.3 ± 9.89-6.7 ± 9.07
Week 24-7.8 ± 10.82-6.2 ± 9.02
Week 28-8.9 ± 10.39-6.5 ± 9.58
Week 32-9.7 ± 10.86-7.0 ± 9.52
Week 36-8.9 ± 11.28-7.4 ± 9.07
Week 40-9.5 ± 11.01-8.2 ± 9.87
Week 44-10.5 ± 10.73-8.8 ± 8.96
Week 48-10.6 ± 10.56-9.3 ± 8.66
Week 52-10.4 ± 10.29-9.3 ± 8.35
SecondaryOL Treatment Phase: Change From Baseline Over Time in Sleep Disturbance Using the PROMIS-SD Short Form 8a T-Score

PROMIS-SD Short Form 8a is a static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has five response options ranging in value from one to five. Direction of responses was not same, sometimes "not at all" represents more sleep disturbance; sometimes "not at all" indicates less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores indicate less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean:50; standard deviation:10. Negative changes in scores indicates improvement. Higher values represent more severe sleep disturbance.

Time frame:
OL Baseline (OL Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · T-score
OL Treatment Phase: Change From Baseline Over Time in Sleep Disturbance Using the PROMIS-SD Short Form 8a T-Score
T-scoreOpen-label (OL) Treatment Phase: Placebo to Seltorexant 20 mgOL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg
Week 4-6.9 ± 8.58-2.8 ± 8.07
Week 8-7.0 ± 8.77-3.5 ± 9.34
Week 12-7.9 ± 9.34-4.7 ± 9.37
Week 16-8.3 ± 9.92-4.6 ± 10.23
Week 20-8.7 ± 10.33-5.0 ± 9.95
Week 24-8.5 ± 10.26-5.1 ± 9.47
Week 28-9.3 ± 10.13-5.1 ± 9.65
Week 32-8.9 ± 10.40-5.7 ± 10.03
Week 36-9.2 ± 11.49-6.1 ± 9.66
Week 40-10.1 ± 10.34-6.4 ± 10.30
Week 44-11.3 ± 11.29-7.1 ± 9.42
Week 48-10.5 ± 10.77-6.8 ± 9.81
Week 52-11.3 ± 10.80-8.0 ± 9.86

Adverse events

Collected over All-cause mortality: double blind (DB): Screening (Day -30) to Day 44, Open label (OL): Day 43 to 2 days post last dose (Week 52.28), Double blind follow up (DB FU): Day 43 to Day 57, Open label follow up (OL FU): Week 52 to Week 54; SAEs/other AEs: DB: Day 1 to 2 days post last dose (Day 44), OL: Day 43 to 2 days after last dose (Week 52.28), DB FU: Day 43 to Day 57, OL FU: Week 52 to Week 54. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double Blind (DB) Treatment Phase: Placebo0/304 (0%)1/303 (0.3%)39/303 (12.9%)
DB Treatment Phase: Seltorexant 20 mg0/284 (0%)1/283 (0.4%)42/283 (14.8%)
OL Treatment Phase: Placebo to Seltorexant 20 mg0/269 (0%)15/269 (5.6%)86/269 (32%)
OL Phase: Seltorexant 20 mg to Seltorexant 20 mg1/253 (0.4%)14/253 (5.5%)90/253 (35.6%)
DB Follow-up Phase: Placebo0/22 (0%)0/22 (0%)1/22 (4.5%)
DB Follow-up Phase: Seltorexant 20 mg0/22 (0%)0/22 (0%)0/22 (0%)
OL Follow-up Phase: Placebo to Seltorexant 20 mg0/228 (0%)0/228 (0%)4/228 (1.8%)
OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg0/225 (0%)0/225 (0%)6/225 (2.7%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgOL Treatment Phase: Placebo to Seltorexant 20 mgOL Phase: Seltorexant 20 mg to Seltorexant 20 mgDB Follow-up Phase: PlaceboDB Follow-up Phase: Seltorexant 20 mgOL Follow-up Phase: Placebo to Seltorexant 20 mgOL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg
Suicide AttemptPsychiatric disorders0/3030/2835/2692/2530/220/220/2280/225
TachycardiaCardiac disorders0/3030/2830/2691/2530/220/220/2280/225
Optic Nerve Sheath HaemorrhageEye disorders0/3030/2830/2691/2530/220/220/2280/225
Lower Gastrointestinal HaemorrhageGastrointestinal disorders0/3030/2830/2691/2530/220/220/2280/225
Chest PainGeneral disorders0/3030/2830/2691/2530/220/220/2280/225
SepsisInfections and infestations0/3030/2830/2691/2530/220/220/2280/225
Septic ShockInfections and infestations0/3030/2830/2691/2530/220/220/2280/225
ConcussionInjury, poisoning and procedural complications0/3030/2830/2691/2530/220/220/2280/225
Skin LacerationInjury, poisoning and procedural complications0/3030/2830/2691/2530/220/220/2280/225
Transaminases IncreasedInvestigations0/3030/2830/2691/2530/220/220/2280/225
Most frequent other events
Most frequent other events
EventDouble Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgOL Treatment Phase: Placebo to Seltorexant 20 mgOL Phase: Seltorexant 20 mg to Seltorexant 20 mgDB Follow-up Phase: PlaceboDB Follow-up Phase: Seltorexant 20 mgOL Follow-up Phase: Placebo to Seltorexant 20 mgOL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg
HeadacheNervous system disorders27/30325/28328/26934/2530/220/221/2285/225
Covid-19Infections and infestations5/3039/28328/26918/2531/220/222/2281/225
NasopharyngitisInfections and infestations4/3034/28322/26922/2530/220/221/2280/225
Weight IncreasedInvestigations4/3035/28313/26921/2530/220/220/2280/225
InfluenzaInfections and infestations4/3031/28311/26914/2530/220/220/2280/225

Baseline characteristics

Safety (DB) analysis set included all randomized participants who received at least 1 dose of study intervention in the DB phase.

Age, Categorical
Age, Categorical(Participants)Double Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgTotal
<=18 years000
Between 18 and 65 years271264535
>=65 years321951
Age, Continuous
Age, Continuous(years)Double Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgTotal
Mean45.9 ± 14.2844.3 ± 13.9945.1 ± 14.15
Sex: Female, Male
Sex: Female, Male(Participants)Double Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgTotal
Female232217449
Male7166137
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgTotal
Hispanic or Latino8275157
Not Hispanic or Latino220206426
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgTotal
American Indian or Alaska Native151328
Asian121022
Native Hawaiian or Other Pacific Islander112
Black or African American151631
White232220452
More than one race213
Unknown or Not Reported262248
Region of Enrollment
Region of Enrollment(Participants)Double Blind (DB) Treatment Phase: PlaceboDB Treatment Phase: Seltorexant 20 mgTotal
Brazil494089
Bulgaria403777
Colombia221941
Czech Republic393978
Mexico151530
Russian Federation111021
South Africa9918
Spain131326
Sweden363470
Taiwan10919
United States5958117
08

Study locations

122 sites
  • Advanced Research Center Inc
    Anaheim, California 92805, United States
  • Synexus
    Cerritos, California 90703, United States
  • Irvine Clinical Research
    Irvine, California 92614, United States
  • Omega Clinical Trials LLC
    La Habra, California 90631, United States
  • Synergy East
    Lemon Grove, California 91945, United States
  • Semel Institute for Neuroscience and Human Behavior
    Los Angeles, California 90048, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • Pacific Research Partners
    Oakland, California 94607, United States
  • North County Clinical Research
    Oceanside, California 92056, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Viking Pharmaceutical Trials Inc. dba Viking Clinical Research
    Temecula, California 92591, United States
  • Connecticut Clinical Trials LLC
    Cromwell, Connecticut 06416, United States
  • University of Connecticut Health Center
    Farmington, Connecticut 06030, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Clinical NeuroScience Solutions Inc
    Jacksonville, Florida 32256, United States
  • Pharmax Research Clinic Inc
    Miami, Florida 33126, United States
  • Medical Research Center of Miami II Inc
    Miami, Florida 33134, United States
  • Phoenix Medical Research, Inc.
    Miami, Florida 33165, United States
  • Galiz Research
    Miami Springs, Florida 33166, United States
  • Bravo Health Care Center
    North Bay Village, Florida 33141, United States
  • APG Research LLC
    Orlando, Florida 32803, United States
  • Combined Research Orlando
    Orlando, Florida 32803, United States
  • Nova Psychiatry INC
    Orlando, Florida 32803, United States
  • Revive Research Institute
    Elgin, Illinois 60123, United States
  • Joliet Center for Clinical Research
    Joliet, Illinois 60435, United States
  • Baber Research Group
    Naperville, Illinois 60563, United States
  • American Medical Research, Inc.
    Oak Brook, Illinois 60523, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62701, United States
  • Louisiana Clinical Research
    Shreveport, Louisiana 71101, United States
  • Adams Clinical
    Watertown, Massachusetts 02472, United States
  • Neurobehavioral Medicine Group
    Bloomfield Hills, Michigan 48302, United States
  • Midwest Research Group - St. Charles Psychiatric Associates
    Saint Charles, Missouri 63301, United States
  • Mid-America Clinical Research, LLC
    St Louis, Missouri 63109, United States
  • PsychCare Consultants Research
    St Louis, Missouri 63128, United States
  • Premier Psychiatric Research Institute, LLC
    Lincoln, Nebraska 68526, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute, LLC.
    Berlin, New Jersey 08009, United States
  • Synexus Clinical Research US Inc
    Jamaica, New York 11432, United States
  • Bioscience Research LLC
    Mount Kisco, New York 10549, United States
  • Haidar Almhana Nieding
    Avon Lake, Ohio 44012, United States
  • The Ohio State University
    Columbus, Ohio 43221, United States
  • Lindner Center of Hope
    Mason, Ohio 45040, United States
  • Oklahoma Clinical Research Center
    Oklahoma City, Oklahoma 73112, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • University of Pennsylvania - Perelman School of Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Relaro Medical Trials
    Dallas, Texas 75243, United States
  • North Texas Clinical Trials
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Red Oak Psychiatry Associates
    Houston, Texas 77090, United States
  • Alpine Research Organization
    Clinton, Utah 84015, United States
  • Green Mountain Research Institute
    Rutland, Vermont 05701, United States
  • CPN - Centro de Pesquisa em Neurociências Ltda
    Belo Horizonte, 30150-270, Brazil
  • CCB Centro Cardiologico de Brasilia Ltda - CCB Cardiologia
    Brasília, 70200-730, Brazil
  • Instituto de Neurologia de Curitiba
    Curitiba, 81210-310, Brazil
  • Universidade Federal do Ceara Hospital Universitario Walter Cantidio
    Fortaleza, 60430-380, Brazil
  • Instituto Mederi de Pesquisa e Saude
    Passo Fundo, 99010-120, Brazil
  • Ruschel Medicina e Pesquisa Clínica Ltda
    Rio de Janeiro, 22270 060, Brazil
  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo
    São Paulo, 04037-003, Brazil
  • Instituto Bairral de Psiquiatria
    São Paulo, 13970-905, Brazil
  • Mental Health Center Prof. Dr. Ivan Temkov
    Burgas, 8001, Bulgaria
  • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
    Cherven Bryag, 5980, Bulgaria
  • State Psychiatric Hospital Kardzhali
    Kardzhali, 6600, Bulgaria
  • Medical center Spectar - Plovdiv EOOD
    Plovdiv, 4000, Bulgaria
  • UMHAT 'Sv. Georgi' EAD
    Plovdiv, 4000, Bulgaria
  • MHC - Sofia, EOOD
    Slivnitsa, 1202, Bulgaria
  • Medical Center St. Naum
    Sofia, 1113, Bulgaria
  • DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
    Sofia, 1408, Bulgaria
  • Medical Center Intermedica, OOD
    Sofia, 1680, Bulgaria
  • Medical center - VAS OOD
    Targovishte, 7700, Bulgaria
  • Mental Health Center - Vratsa EOOD
    Vratsa, 3000, Bulgaria
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA
    Barranquilla, Colombia
  • HOMO - ESE Hospital Mental de Antioquia
    Bello, 051053, Colombia
  • Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda.
    Bogotá, 111166, Colombia
  • Fundacion Centro de Investigacion Clinica CIC
    Medellín, Colombia
  • Psynapsis Salud Mental S.A.
    Pereira, Colombia
  • BRAIN-SOULTHERAPY s.r.o.
    Kladno, 27201, Czechia
  • Neuroterapie KH S R O
    Kutná Hora, 284 01, Czechia
  • A Shine S R O
    Pilsen, 31200, Czechia
  • Clintrial s r o
    Prague, 10000, Czechia
  • Medical Services Prague S R O
    Prague, 16000, Czechia
  • Iecsi S.C.
    Monterrey, 64310, Mexico
  • CRI Centro Regiomontano de Investigacion SC
    Nuevo León, 64060, Mexico
  • Bind Investigaciones S.C.
    San Luis Potosí City, 78213, Mexico
  • Psychoneurological Dispensary of Frunzensky District
    Saint Petersburg, 190013, Russia
  • SPb SBIH 'City Psychoneurological Dispensary # 7 (With Inpatient Facilities)'
    Saint Petersburg, 190020, Russia
  • City Psychiatric Hospital of St. Nikolay Chudotvorets
    Saint Petersburg, 190121, Russia
  • Bekhterev Psychoneurological Research Institute
    Saint Petersburg, 192019, Russia
  • St-Petersburg Bekhterev Psychoneurological Research Institute
    Saint Petersburg, 192019, Russia
  • Psychoneurological dispensary 1
    Saint Petersburg, 199106, Russia
  • Stavropol Region Psychiatric Hospital #2
    Stavropol, 357034, Russia
  • Yaroslavl Region Clinical Psychiatric Hospital
    Yaroslavl, 150003, Russia
  • Farmovs Pty Ltd
    Bloemfontein, 9301, South Africa
  • Iatros International
    Bloemfontein, 9324, South Africa
  • Cape Town Clinical Research Centre
    Cape Town, 7530, South Africa
  • Flexivest 14 Research
    Cape Town, 7530, South Africa
  • DJW Research
    Krugersdorp, 1739, South Africa
  • Stanza Clinical Research Centre : Mamelodi
    Mamelodi East, 0122, South Africa
  • Synexus Watermeyer
    Pretoria, South Africa
  • Somerset West Clinical Research Unit
    Strand, 7140, South Africa
  • Institucion Hosp Hestia Palau
    Barcelona, 08025, Spain

Showing the first 100 of 122 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Apr 2023, 31 months.

Results were first posted in May 2026, 3 years after primary completion. A results delay was requested in Apr 2024.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 31 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Aug 31, 2020
StartActual
Sep 16, 2020
Primary completionActual
Apr 25, 2023
CompletionActual
Apr 30, 2024
Results delay requested
Apr 23, 2024
Results first posted
May 12, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04533529
Responsible party
Sponsor
First posted
Aug 31, 2020
Start date
Sep 16, 2020
Primary completion
Apr 25, 2023
Completion
Apr 30, 2024
Results posted
May 12, 2026
Last update
May 12, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion